Project Grant R44AG067832

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,879 to Oligomerix Inc. to conduct a 13-week oral gavage toxicity study of the drug OLX-07010 in beagle dogs, followed by a 4-week recovery period. The study aims to de-risk a planned 39-week toxicology study required by the FDA for future Phase 1b clinical trials of OLX-07010 in Alzheimer's disease patients. Completing this 13-week dog study will allow Oligomerix to extend the dosing...

This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...

This Project Grant award of $1,257,528 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Novoron Bioscience Inc. is focused on developing a platform to evaluate novel therapies designed to inhibit the propagation and aggregation of pathological tau protein, which is a key driver of Alzheimer's disease and other tauopathies. The platform will leverage human induced pluripotent stem cell (hiPSC)-derived neural organoids, including both wild-type and LRP1 knockout organoids, to...

This R01 project grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $6,467,513.00 to Brigham & Women's Hospital Inc. to continue funding for the Ante-Amyloid Treatment of Alzheimer's Disease (A3) Trial and the Alzheimer Plasma Extension (APEX) Study. The A3 Trial is testing low-dose lecanemab, an amyloid-removing monoclonal antibody, in participants with intermediate brain amyloid levels to determine the optimal window for efficacy and safety of...

The National Institutes of Health Trans-NIH Research Support program awarded a $4,010,262 Project Grant to the University of Illinois to study the role of amyloid precursor protein in neurogenesis and Alzheimer's disease pathology in Down syndrome. The three-year grant will support research examining how overexpression of amyloid precursor protein, which is located on chromosome 21 and thus triplicated in Down syndrome, impacts neural stem cell proliferation, neuronal differentiation, and...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $454,271 to Florida Atlantic University to investigate the role of amyloid precursor protein (APP) and cholesterol homeostasis in synaptic dysfunction and neurodegeneration related to Alzheimer's disease (AD). The research aims to use human neurons derived from induced pluripotent stem cells (hiNs) to systematically study how mutations affecting APP distribution, trafficking, and interaction...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...

This $1,623,119 project grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research characterizing Alzheimer's amyloid-beta oligomer structures through May 2025. The grantee, Georgia Tech Research Corporation, will use solid-state nuclear magnetic resonance and cryo-electron microscopy to achieve high-resolution structural characterization of a unique 150 kDa amyloid-beta oligomer. Researchers will obtain a...

This Project Grant award of $3,064,072.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to establish a non-human primate (NHP) model of alpha-synuclein (αSyn) pathology and test the hypothesis that αSyn pathology in the amygdala affects the regulation of anxiety and mood. The key objectives are to assess time-dependent changes in anxiety-,...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...